“三联”保膀胱模式治疗肌层浸润性膀胱癌的疗效观察
The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer
摘要目的 观察根治性经尿道膀胱肿瘤切除术联合术后放化疗的“三联”模式在肌层浸润性膀胱癌(MIBC)保留膀胱治疗上的效果.方法 回顾性分析2010年5月至2015年5月中日友好医院等3个中心收治的73例肌层浸润性膀胱癌患者资料.28例患者(TMT组)接受了根治性TURB+术后联合放化疗.其中男21例,女7例,年龄(68.9±8.9)岁.T2期16例,T3期12例.同期45例患者(RC组)接受了根治性膀胱切除+尿流改道术,其中男32例,女13例,年龄(66.3±9.6)岁.T2期25例,T3期18例,T4a期2例.分析两种治疗模式对于MIBC预后及生活质量的影响.结果 TMT组的总体生存率为64.3%,肿瘤特异性生存率为78.6%.RC的总体生存率为66.7%,肿瘤特异性生存率为82.2%.总体生存时间分别为(47.9±3.2)个月和(48.5±2.6)个月.两组数据比较差异均无统计学意义(均P>0.05).术后生活质量评分方面,TMT组优于RC组.结论 在严格控制适应证,进行严密的术后随访,并及时进行挽救性膀胱切除术的前提下,“三联”保膀胱疗法可以作为根治性膀胱切除术之外的MIBC患者的一种选择.
更多相关知识
abstractsObjective To explore the effect of radical TURBT combing with concomitant chemoradiotherapy for muscle-invasive bladder cancer (MIBC).Methods From 2010 to 2015,73 patients were diagnosed as MIBC,in which 28 patients (TMT Group) received tri-modality bladder sparing treatment,including 21 males and 7 females,mean age (68.9 ± 8.9) yr.There were 16 cases of T2,12 cases of T3.45 patients (RC Group) received radical cystectomy (RC),including 32 males and 13 females,mean age (66.3 ±9.6) yr.There were 25 cases of T2,18 cases of T3 and 2 cases of T4a.The effect of two treatment modality and influence for patient's life quality were retrospective analysis.Results The overall survival (OS) rate of TMT group was 64.3%,cancer specific survival (CSS) rate was 78.6%.And the OS rate of RC group was 66.7%,CSS rate was 82.2%.There was no statistical difference between two groups.The life quality of TMT group was better than that of RC group.Conclusion In strict control of indication criterion,rigorous postoperative follow-up and timely salvage radical cystectomy,tri-modality therapy can be used as a new option of muscle-invasive bladder cancer.
More相关知识
- 浏览511
- 被引15
- 下载298

相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文